Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Merck Posts Report Revealing Average Price Hikes for Drugs in U.S.

By Ryan Bushey | February 2, 2017

Another drug company unveiled a new strategy for dealing with the drug pricing debate.

Merck & Co. published a report on January 27th called the Pricing Action Transparency Report, which provided details on the average price increase for drugs and vaccines in its portfolio between 2010 and 2016.

The document indicated the average list price change for its product offerings started at 7.4 percent in 2010 hitting a high of 10.5 percent in 2014. Other years saw the list price change hover between 9.2 and 9.8 percent.

Furthermore, the report indicated the average net price change based on wholesale acquisitions minus discounts and rebates varied from 3.4 percent to 6.2 percent whereas average discounts reached 40.9 percent, according to FiercePharma.

Robert McMahon, the president of Merck’s U.S. market, told the Wall Street Journal the company posted these figures because they felt they needed to provide greater transparency into list and net prices since price increases have become an important issue.

Merck didn’t highlight specific drugs in the report, but this announcement follows other drug-makers looking for different approaches to address criticism from the public and politicians on both sides of the aisle over large price hikes for important drugs.

Firms like AbbVie, Takeda, Novo Nordisk, and Allergan have pledged to limit any price raises to annual single-digit percentages while Johnson & Johnson will release their own transparency report sometime this month with a layout similar to Merck’s.

You can view Merck’s chart below. The company plans on updating these numbers every January going forward.

Source: Merck


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50